Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations

A. Ceriello, E. Marchi, E. Palazzni, A. Quatraro, D. Giugliano

Research output: Contribution to journalArticle

Abstract

Alteration of antithrombin III (ATIII) activity, glycemia level dependent, exists in diabetes mellitus. In this study the ability of a low molecular weight heparin (LMWH) (Fluxum, Alfa-Wassermann s.p.A., Bologna, Italy), as well as unfractioned heparin, to preserve ATIII activity from glucose-induced alterations, both in vitro and in vivo, is reported. The subcutaneous and intravenous LMWH and heparin administration increases basal depressed ATIII activity in diabetic patients. Heparin shows an equivalent effect on both anti-IIa and anti-Xa activity of ATIII, while LMWH is more effective in preserving the anti-Xa activity. Similarly, heparin preserves ATIII activity from hyperglycemia-induced alterations, during hyperglycemic clamp, and LMWH infusion is able to preserve a significant amount of anti-Xa activity from glucose-induced alterations. Since diabetic patients show a high incidence of thrombotic accidents, LMWH appears to be a promising innovation for the prevention of diabetic thrombophylia.

Original languageEnglish
Pages (from-to)86-92
Number of pages7
JournalDiabete et Metabolisme
Volume16
Issue number2
Publication statusPublished - 1990

Fingerprint

Antithrombin III
Low Molecular Weight Heparin
Hyperglycemia
Heparin
Glucose
Italy
Accidents
Diabetes Mellitus
Incidence

Keywords

  • antithrombin III, diabetes, low molecular weight heparin
  • diabetic thrombophylia
  • heparin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations. / Ceriello, A.; Marchi, E.; Palazzni, E.; Quatraro, A.; Giugliano, D.

In: Diabete et Metabolisme, Vol. 16, No. 2, 1990, p. 86-92.

Research output: Contribution to journalArticle

Ceriello, A, Marchi, E, Palazzni, E, Quatraro, A & Giugliano, D 1990, 'Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations', Diabete et Metabolisme, vol. 16, no. 2, pp. 86-92.
Ceriello, A. ; Marchi, E. ; Palazzni, E. ; Quatraro, A. ; Giugliano, D. / Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations. In: Diabete et Metabolisme. 1990 ; Vol. 16, No. 2. pp. 86-92.
@article{00c7c0b5c56942bfa7b2d7fc7347b64c,
title = "Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations",
abstract = "Alteration of antithrombin III (ATIII) activity, glycemia level dependent, exists in diabetes mellitus. In this study the ability of a low molecular weight heparin (LMWH) (Fluxum, Alfa-Wassermann s.p.A., Bologna, Italy), as well as unfractioned heparin, to preserve ATIII activity from glucose-induced alterations, both in vitro and in vivo, is reported. The subcutaneous and intravenous LMWH and heparin administration increases basal depressed ATIII activity in diabetic patients. Heparin shows an equivalent effect on both anti-IIa and anti-Xa activity of ATIII, while LMWH is more effective in preserving the anti-Xa activity. Similarly, heparin preserves ATIII activity from hyperglycemia-induced alterations, during hyperglycemic clamp, and LMWH infusion is able to preserve a significant amount of anti-Xa activity from glucose-induced alterations. Since diabetic patients show a high incidence of thrombotic accidents, LMWH appears to be a promising innovation for the prevention of diabetic thrombophylia.",
keywords = "antithrombin III, diabetes, low molecular weight heparin, diabetic thrombophylia, heparin",
author = "A. Ceriello and E. Marchi and E. Palazzni and A. Quatraro and D. Giugliano",
year = "1990",
language = "English",
volume = "16",
pages = "86--92",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",
number = "2",

}

TY - JOUR

T1 - Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations

AU - Ceriello, A.

AU - Marchi, E.

AU - Palazzni, E.

AU - Quatraro, A.

AU - Giugliano, D.

PY - 1990

Y1 - 1990

N2 - Alteration of antithrombin III (ATIII) activity, glycemia level dependent, exists in diabetes mellitus. In this study the ability of a low molecular weight heparin (LMWH) (Fluxum, Alfa-Wassermann s.p.A., Bologna, Italy), as well as unfractioned heparin, to preserve ATIII activity from glucose-induced alterations, both in vitro and in vivo, is reported. The subcutaneous and intravenous LMWH and heparin administration increases basal depressed ATIII activity in diabetic patients. Heparin shows an equivalent effect on both anti-IIa and anti-Xa activity of ATIII, while LMWH is more effective in preserving the anti-Xa activity. Similarly, heparin preserves ATIII activity from hyperglycemia-induced alterations, during hyperglycemic clamp, and LMWH infusion is able to preserve a significant amount of anti-Xa activity from glucose-induced alterations. Since diabetic patients show a high incidence of thrombotic accidents, LMWH appears to be a promising innovation for the prevention of diabetic thrombophylia.

AB - Alteration of antithrombin III (ATIII) activity, glycemia level dependent, exists in diabetes mellitus. In this study the ability of a low molecular weight heparin (LMWH) (Fluxum, Alfa-Wassermann s.p.A., Bologna, Italy), as well as unfractioned heparin, to preserve ATIII activity from glucose-induced alterations, both in vitro and in vivo, is reported. The subcutaneous and intravenous LMWH and heparin administration increases basal depressed ATIII activity in diabetic patients. Heparin shows an equivalent effect on both anti-IIa and anti-Xa activity of ATIII, while LMWH is more effective in preserving the anti-Xa activity. Similarly, heparin preserves ATIII activity from hyperglycemia-induced alterations, during hyperglycemic clamp, and LMWH infusion is able to preserve a significant amount of anti-Xa activity from glucose-induced alterations. Since diabetic patients show a high incidence of thrombotic accidents, LMWH appears to be a promising innovation for the prevention of diabetic thrombophylia.

KW - antithrombin III, diabetes, low molecular weight heparin

KW - diabetic thrombophylia

KW - heparin

UR - http://www.scopus.com/inward/record.url?scp=0025283042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025283042&partnerID=8YFLogxK

M3 - Article

C2 - 2196192

AN - SCOPUS:0025283042

VL - 16

SP - 86

EP - 92

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 2

ER -